AnnouncementsANNOUNCEMENT Delegates from Tamarisk  will be attending BIO 2018!  Delegates will also be participating in the 1-on-1 Partnering sessions and are quite enthusiastic to share more about our recent critical advances with the MxBA technology.  If you would like to schedule a meeting to learn more, please contact us today.

Oral InsulinMxBA™ Platform | Maximum Bioavailability (Revised 04.29.16) Oral Drug Delivery Technology | Click Here

PRESS RELEASE | Los Angeles, April 25, 2016  Oral Drug Delivery System |  “Independent Rat Study Finds 54% Oral Insulin Relative Bioavailability Using Tamarisk’s MxBA™ Platform Technology”  Click Here or Play Video

Tamarisk ShareholdersShareholder Relations Get the latest updates  | Click Here

New Oral Drug Delivery System | Tamarisk’s MxBA™ Platform

Tamarisk Technologies Group is an early stage drug delivery technology company with headquarters based in Santa Barbara, California. Our patented MxBA™ oral drug delivery system is a platform technology that maximizes the bioavailability of a wide range of oral drugs, including both small molecules and larger bio-molecules and BCS Classes II & IV drugs.

At the core of Tamarisk’s MxBA™ technology is an alginate particle carrier designed to encapsulate, protect and transport payload drug candidates within the GI. Unique to Tamarisk are the added excipient substrates engineered into the particles to provide targeted GI delivery, added preservation and transfer of payload drugs and facilitation of novel absorption pathways.

By increasing absorption and bioavailability on currently difficult to administer therapeutics, Tamarisk’s MxBA™ oral drug delivery system will be the next generation enabler for the pharmaceutical industry.

To date, Tamarisk has conducted numerous bench, cell culture, and small animal studies that confirm our particle consistently delivers significantly better than the control.  In a rat study recently performed at Charles River,  the system was used to study the increased bioavailability of Resveratrol, confirming previously observed results. However, Tamarisk is now primarily focused on completing it’s work with oral protein delivery, and based on numerous studies conducted, we are confident the MxBA™ oral drug delivery platform will soon be a preferred solution for use with both small and large molecules, including incretin-like peptides such as GLP and GIP.

Solving the Problem

Because of the various challenges an orally administered drug faces on its journey through the GI, normally only a small percentage of the payload will reach the bloodstream in a desired bioactive form. This is substantially reduced when the drug’s structure is both unfamiliar and quantitatively challenging to the normal GI absorption mechanisms.  These challenges require many next generation drugs, such as peptides, proteins and monoclonal antibodies, to be administered through undesirable injection technologies or in such large oral dosages that patients are exposed to a myriad of undesirable side effects.

Effective oral bioavailability will drive a major surge in acceptance, patient compliance and sales for these high valued drugs. Tamarisk Technologies is well positioned to capitalize on its disruptive broad-spectrum MxBA™ platform technology to build a portfolio of drug delivery partnership opportunities with a multitude of pharmaceutical companies.


Tamarisk has developed and patented a platform oral drug delivery system that uses a strategic combination of natural excipients to empower novel GI transcytosis mechanisms, resulting in substantially increased oral bioavailability.

Target Markets:

  • Small molecule pharmaceuticals
  • Over-the-counter vitamins and nutraceuticals
  • Biologics (proteins/peptides, monoclonal antibodies)
  • Generics
  • Vaccines

All rights reserved. Unless otherwise noted, copyrights for the Best oral drug deliverydocuments, logos, and graphic designs available on this web site are owned by Tamarisk Technologies Group, LLC.